Richard Bruce Silverman | |
---|---|
Born | |
Nationality | American |
Alma mater | Pennsylvania State University (B.S.) Harvard University (Ph.D.) |
Known for | Pregabalin (brand name Lyrica) |
Awards | Perkin Medal (2009), Centenary Prize, Royal Society of Chemistry (2013), Excellence in Medicinal Chemistry Prize, Israel Chemical Society (2014), Award for Creative Invention of the American Chemical Society (2017), Tetrahedron Prize for Creativity in Organic Chemistry (2021), Elected member, National Academy of Sciences (2023) |
Scientific career | |
Fields | Chemistry |
Institutions | Northwestern University |
Doctoral advisor | David Dolphin |
External videos | |
---|---|
"Richard B. Silverman, Basic Science to Blockbuster Drug", National Academy of Inventors |
Richard Bruce Silverman (born May 12, 1946) is the Patrick G. Ryan/Aon Professor of Chemistry at Northwestern University. His group's main focus is basic and translational research into central nervous system disorders and cancer. He is known for the discovery of pregabalin, which is marketed by Pfizer under the brand name Lyrica. [1]
Silverman attended Central High School of Philadelphia. [2] Silverman received his B.S. in chemistry from Pennsylvania State University in 1968. He spent one semester at Harvard University before being drafted and serving as a United States Army Physical Sciences Assistant at the Walter Reed Army Institute of Research from January 1969 until his honorable discharge in January 1971. In June 1974, he received his Ph.D. from Harvard University in organic chemistry with advisor David Dolphin. He then spent two years as a postdoctoral fellow with Robert Abeles in biochemistry at Brandeis University. [3]
Silverman has been teaching and doing research at Northwestern since 1976. He became both professor of chemistry and professor of biochemistry, molecular biology, and cell biology in 1986. He has held several named professorships. He was the Arthur Andersen Professor of Chemistry from 1988 to 1996, the Charles Deering McCormick Professor of Teaching Excellence from 2001 to 2003, [4] and the John Evans Professor of Chemistry beginning from 2004 to 2015. [5] He was named the inaugural Patrick G. Ryan/Aon Professor as of September 1, 2015. [3]
The primary focus in Silverman's laboratory is basic research into central nervous system disorders, including Amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, and epilepsy. [6] Other research areas include cancer (melanoma and hepatocellular carcinoma). He has developed novel approaches to the elucidation of enzyme-catalyzed reactions in organic chemistry. [7] He is interested in understanding and developing mechanisms of enzyme inhibition. [8]
Silverman has published about 400 research articles. He has been awarded 130 patents. He has written 3 books (one in the third edition): Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology (CRC Press; 1988), Organic Chemistry of Drug Design and Drug Action (Academic Press; 1992, 2004, 2014), and Organic Chemistry of Enzyme-Catalyzed Reactions (Academic Press; 2000, 2002; see the Published works section, below). He is active on the editorial boards of a number of scholarly journals. [7]
Silverman is known for inventing the drug pregabalin as a possible treatment for epileptic seizures. [6] During 1988-1990, Ryszard Andruszkiewicz, a visiting research fellow, synthesized a series of molecules for Silverman. [9] One looked promising. [10] The molecule was transported into the brain, where it activated the enzyme L-glutamate decarboxylase. Silverman anticipated that the enzyme would increase production of the inhibitory neurotransmitter GABA and block convulsions. [6] Eventually, the set of molecules were sent to Parke-Davis Pharmaceuticals for testing. In addition to treating seizures, pregabalin was found to be effective in treating fibromyalgia pain, neuropathic pain, and generalized anxiety disorder. [6] It was approved by the FDA in 2004 and marketed by Pfizer (which bought Parke-Davis) under the trade name Lyrica. [6] [10]
Research has shown that the mechanism of the drug is more complicated than originally anticipated. [11] In addition to its effects on GABA-AT substrate behavior, pregabalin binds to calcium channels and blocks glutamate release. GABA is potentiated, but through a different mechanism than originally suspected. [12] [13]
Silverman has received numerous teaching awards from Northwestern University, including the following:
Lyrica royalties paid to Northwestern, and a gift from Silverman himself, have supported the Silverman Hall for Molecular Therapeutics and Diagnostics at Northwestern University. Silverman Hall, which opened in 2009, was designed to be a collaborative and interdisciplinary facility housing researchers from chemistry, biology, and engineering. [6] [27]
Pregabalin, sold under the brand name Lyrica among others, is an anticonvulsant, analgesic and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, opioid withdrawal and generalized anxiety disorder (GAD). Pregabalin also has antiallodynic properties. Its use in epilepsy is as an add-on therapy for partial seizures. It is a gabapentinoid medication and acts by inhibiting certain calcium channels. When used before surgery, it reduces pain but results in greater sedation and visual disturbances. It is taken by mouth.
Frank Henry Westheimer was an American chemist. He taught at the University of Chicago from 1936 to 1954, and at Harvard University from 1953 to 1983, becoming the Morris Loeb Professor of Chemistry in 1960, and Professor Emeritus in 1983. The Westheimer medal was established in his honor in 2002.
Christopher Abell was a British biological chemist who was a professor of biological chemistry at the Yusuf Hamied Department of Chemistry and Todd-Hamied Fellow of Christ's College, Cambridge. On his 2016 election to the Royal Society, Abell's research was described as having "changed the face of drug discovery."
Jonathan S. Dordick is an institute professor of chemical and biological engineering at Rensselaer Polytechnic Institute and holds joint appointments in the departments of biomedical engineering and biological sciences. In 2008 he became director of the Center for Biotechnology and Interdisciplinary Studies. In 2012 Dordick became the vice president for research at RPI. He became Special Advisor to the RPI President for Strategic Initiatives in 2018,
Dale Lester Boger is an American medicinal and organic chemist and former chair of the Department of Chemistry at The Scripps Research Institute in La Jolla, CA.
Bruce Eliot Maryanoff FRSC is an American medicinal and organic chemist.
William Platt Jencks was an American biochemist. He was noted particularly for his work on enzymes, using concepts drawn from organic chemistry to understand their mechanisms.
Charon Robin Ganellin FRS is a British medicinal chemist, and Emeritus Smith Kline and French Professor of Medicinal Chemistry, at University College London.
JoAnne Stubbe is an American chemist best known for her work on ribonucleotide reductases, for which she was awarded the National Medal of Science in 2009. In 2017, she retired as a Professor of Chemistry and Biology at the Massachusetts Institute of Technology.
Cynthia "Cyndie" Anne Maryanoff is an American organic and materials chemist. Among other awards, she received the 2015 Perkin Medal for outstanding work in applied chemistry in the U.S.A.
Stephen James Lippard is the Arthur Amos Noyes Emeritus Professor of Chemistry at the Massachusetts Institute of Technology. He is considered one of the founders of bioinorganic chemistry, studying the interactions of nonliving substances such as metals with biological systems. He is also considered a founder of metalloneurochemistry, the study of metal ions and their effects in the brain and nervous system. He has done pioneering work in understanding protein structure and synthesis, the enzymatic functions of methane monooxygenase (MMO), and the mechanisms of cisplatin anticancer drugs. His work has applications for the treatment of cancer, for bioremediation of the environment, and for the development of synthetic methanol-based fuels.
Sir Shankar Balasubramanian is an Indian-born British chemist and Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry at the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College, Cambridge. He is recognised for his contributions in the field of nucleic acids. He is scientific founder of Solexa and Cambridge Epigenetix.
Subramania Ranganathan (1934–2016), popularly known as Ranga, was an Indian bioorganic chemist and professor and head of the department of chemistry at the Indian Institute of Technology, Kanpur. He was known for his studies on synthetic and mechanistic organic chemistry and was an elected fellow Indian National Science Academy, National Academy of Sciences, India and the Indian Academy of Sciences The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 1977, for his contributions to chemical sciences.
Govindasamy Mugesh is an Indian inorganic and physical chemist, a professor and the head of the Mugesh Laboratory attached to the department of Inorganic and Physical Chemistry at the Indian Institute of Science. He is known for his studies on mechanism of thyroid hormone action and is an elected fellow of the Indian Academy of Sciences, Indian National Science Academy, Royal Society of Chemistry and the National Academy of Sciences, India. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2012, for his contributions to chemical sciences. In 2019, he was awarded the Infosys Prize in Physical Sciences for his seminal work in the chemical synthesis of small molecules and nanomaterials for biomedical applications.
Paul Gassman was an American chemist. He is best known for his research in the field of organic chemistry and his service as president of the American Chemical Society and is listed among notable alumni by the Cornell University Graduate School.
Sarah E. O'Connor is an American molecular biologist working to understand the molecular machinery involved in assembling important plant natural products – vinblastine, morphine, iridoids, secologanin – and how changing the enzymes involved in this pathway lead to diverse analogs. She was a Project Leader at the John Innes Centre in the UK between 2011 and 2019. O'Connor was appointed by the Max Planck Society in 2018 to head the Department of Natural Product Biosynthesis at the Max Planck Institute for Chemical Ecology in Jena, Germany, taking up her role during 2019.
Alexandros Makriyannis is an American biochemist and professor of chemistry and chemical biology in the department of medicinal chemistry at Northeastern University in Boston, Massachusetts, where he directs the Center for Drug Discovery and holds the George Behrakis Chair of Pharmaceutical Biotechnology. His research has focused on the biochemical basis of the endocannabinoid system and on the development of synthetic cannabinoids.
Barry Victor Lloyd Potter MAE FMedSci is a British chemist, who is Professor of Medicinal & Biological Chemistry at the University of Oxford, Wellcome Trust Senior Investigator and a Fellow of University College, Oxford.
Iwao Ojima is a Japanese-American chemist and university distinguished professor at the State University of New York at Stony Brook. He has been widely recognized for his seminal contributions to a range of chemical research at the multifaceted interfaces of chemical synthesis and life sciences. As rare accomplishments, he has received four National Awards from the American Chemical Society in four different fields of research. He is also serving as the director of the Institute of Chemical Biology and Drug Discovery (ICB&DD), as well as the president of the Stony Brook Chapter of the National Academy of Inventors.
CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction, infantile spasms, and Tourette syndrome.